CoChat
Sign Up
Cited by 166SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studiesCOVID-19 Clinical Research Studies

The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.

Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study

Open access
Stowe, Julia, Andrews, Nick, Kirsebom, Freja, Ramsay, Mary, Bernal, Jamie Lopez·2022·Nature Communications
DOI 10.1038/s41467-022-33378-7PMC PMC9523190

Published version of a preprint

Open this paper in CoChat — free accountOpen PDF

Abstract

The Omicron variant has been associated with reduced vaccine effectiveness (VE) against mild disease with rapid waning. Meanwhile Omicron has also been associated with milder disease. Protection against severe disease has been substantially higher than protection against infection with previous variants. We used a test-negative case-control design to estimate VE against hospitalisation with the Omicron and Delta variants using PCR testing linked to hospital records. We investigated the impact of increasing the specificity and severity of hospitalisation definitions on VE. Among 18–64-year-olds using cases admitted via emergency care, VE after a 3rd dose peaked at 82.4% and dropped to 53.6% by 15+ weeks after the 3rd dose; using all admissions for > = 2 days stay with a respiratory code in the primary diagnostic field VE ranged from 90.9% to 67.4%; further restricting to those on oxygen/ventilated/intensive care VE ranged from 97.1% to 75.9%. Among 65+ year olds the equivalent VE estimates were 92.4% to 76.9%; 91.3% to 85.3% and 95.8% to 86.8%. Here we show that with milder Omicron disease contamination of hospitalisations with incidental cases is likely to reduce VE estimates. VE estimates increase, and waning is reduced, when specific hospitalisation definitions are used.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-022-33378-7

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Vaccine effectiveness estimates with 95% confidence intervals 7+ days after a 3rd dose against symptomatic disease and different hospitalisation outcomes by age group and variant. ECDS Emergency Care Dataset—administrative data from emergency departments, SUS Secondary Users Service—administrative data from all secondary care which is coded on discharge, ECDS All all admissions through emergency care. ECDS Resp Coded respiratory SNOMED coded admission through emergency care, SUS All admitted with a respiratory ICD code, SUS Not Primary admitted with a respiratory ICD code not in the primary diagnosis field, SUS Primary admitted with a respiratory ICD code in the primary diagnosis field. 0 days, 1+ days, 2+ days, 3+ days: length of stay, for example, 1+ means at least one overnight stay. Vaccine effectiveness estimates are adjusted using sex, index of multiple deprivation (quintile), ethnic group, care home residence status (for age 65+), geographic region (NHS region), period (calendar week of test), health and social care worker status (for age <65), clinical risk group status (for age <65), clinically extremely vulnerable, severely immunosuppressed, and previously testing positive.
Fig. 1 Vaccine effectiveness estimates with 95% confidence intervals 7+ days after a 3rd dose against symptomatic disease and different hospitalisation outcomes by age group and variant. ECDS Emergency Care Dataset—administrative data from emergency departments, SUS Secondary Users Service—administrative data from all secondary care which is coded on discharge, ECDS All all admissions through emergency care. ECDS Resp Coded respiratory SNOMED coded admission through emergency care, SUS All admitted with a respiratory ICD code, SUS Not Primary admitted with a respiratory ICD code not in the primary diagnosis field, SUS Primary admitted with a respiratory ICD code in the primary diagnosis field. 0 days, 1+ days, 2+ days, 3+ days: length of stay, for example, 1+ means at least one overnight stay. Vaccine effectiveness estimates are adjusted using sex, index of multiple deprivation (quintile), ethnic group, care home residence status (for age 65+), geographic region (NHS region), period (calendar week of test), health and social care worker status (for age <65), clinical risk group status (for age <65), clinically extremely vulnerable, severely immunosuppressed, and previously testing positive.CC BY · PubMed Central
Fig. 2 Vaccine effectiveness estimates with 95% confidence intervals against hospitalisations using ECDS by age group and manufacturer (all symptomatic controls, Omicron only). a 18–64: Two doses of ChAdOx1-S with a BNT162b2 or mRNA-1273 third dose, b 18–64: two doses of BNT162b2 with a BNT162b2 or mRNA-1273 third dose, c 65 and older: two doses of ChAdOx1-S with a BNT162b2 or mRNA-1273 third dose, d 65 and older: two doses of BNT162b2 with a BNT162b2 or mRNA-1273 third dose, Vaccine effectiveness estimates are adjusted using sex, index of multiple deprivation (quintile), ethnic group, care home residence status (for age 65+), geographic region (NHS region), period (calendar week of the test), health and social care worker status (for age <65), clinical risk group status (for age <65), clinically extremely vulnerable, severely immunosuppressed, and previously tested positive.
Fig. 2 Vaccine effectiveness estimates with 95% confidence intervals against hospitalisations using ECDS by age group and manufacturer (all symptomatic controls, Omicron only). a 18–64: Two doses of ChAdOx1-S with a BNT162b2 or mRNA-1273 third dose, b 18–64: two doses of BNT162b2 with a BNT162b2 or mRNA-1273 third dose, c 65 and older: two doses of ChAdOx1-S with a BNT162b2 or mRNA-1273 third dose, d 65 and older: two doses of BNT162b2 with a BNT162b2 or mRNA-1273 third dose, Vaccine effectiveness estimates are adjusted using sex, index of multiple deprivation (quintile), ethnic group, care home residence status (for age 65+), geographic region (NHS region), period (calendar week of the test), health and social care worker status (for age <65), clinical risk group status (for age <65), clinically extremely vulnerable, severely immunosuppressed, and previously tested positive.CC BY · PubMed Central
Fig. 3 Vaccine effectiveness estimates with 95% confidence intervals against hospitalisations >=2 days and >=2 days and on oxygen/ventilated/on ICU using SUS by age group and manufacturer (all symptomatic controls, Omicron only). Vaccine effectiveness estimates are adjusted using sex, index of multiple deprivation (quintile), ethnic group, care home residence status (for age 65+), geographic region (NHS region), period (calendar week of the test), health and social care worker status (for age <65), clinical risk group status (for age <65), clinically extremely vulnerable, severely immunosuppressed, and previously tested positive. a 18–64: two doses of ChAdOx1-S with a BNT162b2 or mRNA-1273 third dose, b 18–64: two doses of BNT162b2 with a BNT162b2 or mRNA-1273 third dose, c 65 and older: two doses of ChAdOx1-S with a BNT162b2 or mRNA-1273 third dose, d 65 and older: two doses of BNT162b2 with a BNT162b2 or mRNA-1273 third dose.
Fig. 3 Vaccine effectiveness estimates with 95% confidence intervals against hospitalisations >=2 days and >=2 days and on oxygen/ventilated/on ICU using SUS by age group and manufacturer (all symptomatic controls, Omicron only). Vaccine effectiveness estimates are adjusted using sex, index of multiple deprivation (quintile), ethnic group, care home residence status (for age 65+), geographic region (NHS region), period (calendar week of the test), health and social care worker status (for age <65), clinical risk group status (for age <65), clinically extremely vulnerable, severely immunosuppressed, and previously tested positive. a 18–64: two doses of ChAdOx1-S with a BNT162b2 or mRNA-1273 third dose, b 18–64: two doses of BNT162b2 with a BNT162b2 or mRNA-1273 third dose, c 65 and older: two doses of ChAdOx1-S with a BNT162b2 or mRNA-1273 third dose, d 65 and older: two doses of BNT162b2 with a BNT162b2 or mRNA-1273 third dose.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 3

  1. World Health Organization. COVID-19 Weekly Epidemiological Update, Edition 82 (World Health Organization, 2022).
  2. Wilhelm, A. et al. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies. EBioMedicine. 82, 104158 (2022). · DOI · Paper page
  3. Andrews, N. et al. Duration of protection against mild and severe disease by Covid-19 vaccines. New Engl. J. Med. 386, 340–350 (2022). · DOI · Paper page

Cited by

Sorted by citations

See all 166

Related

See all

Metadata

Authors
Stowe, J., Andrews, N., Kirsebom, F., Ramsay, M., & Bernal, J. L.
Affiliations
  • UK Health Security Agency (GB)
  • London School of Hygiene & Tropical Medicine (GB)
  • National Institute for Health and Care Research (GB)
Corresponding author
Stowe, Julia
ORCID
Venue
Nature Communications
Publisher
Springer Science and Business Media LLC
Published
2022-09-30
Volume
13
Issue
1
Pages
5736-5736
ISSN
2041-1723 (ISSN-L)
DOI
10.1038/s41467-022-33378-7
PMC
PMC9523190
OpenAlex
W4298145582
Cited by
166
References
24
Citations by year
2026: 7 · 2025: 19 · 2024: 43 · 2023: 67 · 2022: 30
FWCI
19.40
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • medRxiv (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords
COVID-19 vaccines, vaccine effectiveness, Omicron variant, Delta variant, hospitalization, waning vaccine effectiveness, test-negative case-control design, third dose, older adults, emergency department admission
MeSH terms
COVID-19, SARS-CoV-2, COVID-19 Vaccines, Hospitalization, Humans, Oxygen, Vaccination, Case-Control Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review